# OnCo record hypogammaglobulinaemia (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/hypogammaglobulinaemia/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "hypogammaglobulinaemia" ;
  schema:name "Hypogammaglobulinaemia and infection risk after B-cell therapies"@en ;
  schema:alternateName "hypogammaglobulinemia"@en, "low immunoglobulins"@en, "low IgG"@en, "immunoglobulin replacement"@en, "IVIG"@en, "intravenous immunoglobulin"@en, "B-cell depletion"@en, "B-cell aplasia"@en, "infection risk"@en, "opportunistic infections"@en, "infection prophylaxis"@en, "antimicrobial prophylaxis"@en, "antiviral prophylaxis"@en, "PJP prophylaxis"@en, "Pneumocystis prophylaxis"@en, "CMV reactivation"@en, "cytomegalovirus"@en, "vaccine responses"@en, "revaccination"@en ;
  schema:description "A shortage of antibodies because treatment has wiped out the B cells or plasma cells that make them, as CD19 CAR-T, CD20 antibodies and BCMA therapies deliberately do. It leaves patients prone to infections, sometimes for years, and is managed with immunoglobulin infusions."@en ;
  schema:url <https://onco.cc/terms/hypogammaglobulinaemia/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hypogammaglobulinemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Hypogammaglobulinemia>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/immunoglobulin-replacement-therapy>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/car-t-cell-therapy>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention> ;
  onco:related <https://onco.cc/terms/t-cell-exhaustion-term/>, <https://onco.cc/terms/cytopenias/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/technologies/rejuv-tx-b-cell-aplasia-and-immunoglobulin/>, <https://onco.cc/technologies/rejuv-tx-revaccination/> ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/nodal-marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/rejuvenation/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/teclistamab/> .